

Meet The Professors: Management of Chronic Lymphocytic Leukemia

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. A recent press release on the Phase III ELEVATE-RR trial comparing acalabrutinib to ibrutinib for patients with previously treated, high-risk chronic lymphocytic leukemia (CLL) reported which of the following outcomes?**
 - Significantly lower rate of atrial fibrillation with ibrutinib
 - Significantly lower rate of atrial fibrillation with acalabrutinib
 - Similar rates of atrial fibrillation with ibrutinib and acalabrutinib
- 2. Which of the following regimens was compared to bendamustine/rituximab in the Phase III MURANO study in patients with relapsed/refractory CLL?**
 - Venetoclax/rituximab
 - Venetoclax/obinutuzumab
 - Bendamustine/obinutuzumab
- 3. Which of the following adverse effects is most likely to be seen in patients receiving venetoclax therapy?**
 - Ocular toxicity
 - Tumor lysis syndrome
 - Hand-foot syndrome
- 4. Updated data presented at the 2020 American Society of Hematology Virtual Annual Conference from the Phase III CLL14 study comparing venetoclax/obinutuzumab to chlorambucil/obinutuzumab for patients with previously untreated CLL and coexisting medical conditions support the benefit of fixed-duration therapy with venetoclax/obinutuzumab in which of the following subsets of patients?**
 - Patients who have detectable minimal residual disease (MRD)
 - Patients who have undetectable MRD